<DOC>
	<DOCNO>NCT02285166</DOCNO>
	<brief_summary>The purpose survey determine incidence rate cardiovascular ( CV ) event associate long-term treatment without omega-3 fatty acid ethyl ester ( Lotriga Granular Capsules ) high-risk hyperlipidemic patient treat statin daily medical practice .</brief_summary>
	<brief_title>Specified Drug-use Survey Granular Capsule Formulation Omega-3 Fatty Acid Ethyl Esters : OCEAN3</brief_title>
	<detailed_description>This survey plan determine incidence rate cardiovascular ( CV ) event associate long-term treatment omega-3 fatty acid ethyl ester ( Lotriga Granular Capsules ) high-risk hyperlipidemic patient treat statin daily medical practice . The incidence rate CV event patient treated standard anti-hyperlipidemic therapy Lotriga investigate survey compare event rate two patient group information . For adult , 2 g omega-3 fatty acid ethyl ester usually administer orally daily immediately meal . However , dose increase twice daily ( dose 2 g ) depend patient 's triglyceride ( TG ) level .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hypolipidemic Agents</mesh_term>
	<criteria>Patients meet follow criterion include survey : 1 . Patients hyperlipidemia statin therapy 2 . Outpatients 3 . Male patient age ≥ 50 year female patient age ≥ 60 year 4 . Patients fast TG level ≥ 150 mg/dL ( within 3 month prior start observation period ) 5 . Patients least two follow risk factor : Hypertension Type 2 diabetes mellitus Chronic kidney disease Prior history myocardial infarction angina pectoris Prior history cerebral infarction Peripheral arterial disease Patients meet follow criterion exclude survey : 1 . Patients experience coronary artery disease within 1 month prior start observation period 2 . Patients experience cerebrovascular disease within 1 month prior start observation period 3 . Patients undergone heart surgery revascularization surgery ( include coronary artery intervention peripheral arterial intervention ) within 1 month prior start observation period 4 . Patients plan undergo heart surgery revascularization surgery ( include coronary artery intervention peripheral arterial intervention ) 5 . Patients malignant tumor currently treatment 6 . Patients receive eicosapentaenoic acid ( hereinafter , EPA ) product within 1 month prior start observation period , patient plan receive treatment EPA product start observation period 7 . Patients hemorrhage ( e.g. , hemophilia , capillary fragility , gastrointestinal ulcer , urinary tract hemorrhage , hemoptysis , vitreous hemorrhage ) 8 . Patients prior history hypersensitivity ingredient Lotriga ( Lotrigatreated patient ) 9 . Patients prior history treatment Lotriga</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pharmaocological therapy</keyword>
</DOC>